Skip to main content
. Author manuscript; available in PMC: 2020 Sep 11.
Published in final edited form as: Nat Rev Cancer. 2018 Feb 16;18(5):283–295. doi: 10.1038/nrc.2018.10

Figure 1 ∣. Allo-HSCT and GVHD.

Figure 1 ∣

Patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) receive a pretransplant regimen including chemotherapeutic agents with or without total body irradiation and/or antibodies. Patients receive donor haematopoietic stem cells after this pretransplant regimen. Graft-versus-host disease (GVHD) occurs when alloreactive donor T cells attack host tissues, including the skin, liver, gastrointestinal tract, central nervous system, thymus, ovary or testis as well as the haematopoietic system.